Bacterial infections, alloimmunity, and transplantation tolerance

Transplantation Reviews

Volumn 25, Issue 1, 2011, Pages 27-35

  Ahmed, Emily B ^a   Daniels, Melvin ^a   Alegre, Maria Luisa ^b   Chong, Anita S ^a  

^a THE UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; IMMUNOSUPPRESSIVE AGENT; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 11; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; ALLOIMMUNITY; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; EXPERIMENTAL MODEL; GRAFT REJECTION; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; LISTERIOSIS; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; T LYMPHOCYTE; TRANSPLANTATION TOLERANCE;

EID: 78649641402     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2010.10.003     Document Type: Review

References (80)

1. Ahmed E.B., Alegre M.L., Chong A.S. Role of bacterial infections in allograft rejection. Expert Rev Clin Immunol 2008, 4:281-293.
2. Burns A.M., Ma L., Li Y., et al. Memory alloreactive B cells and alloantibodies prevent anti-CD154-mediated allograft acceptance. J Immunol 2009, 182:1314-1324.
3. Goldstein D. Role of MyD88 and Trif in acute allograft rejection: glass half full or empty?. Eur J Immunol 2006, 36:2820.
4. Wang T., Chen L., Ahmed E., et al. Prevention of allograft tolerance by bacterial infection with Listeria monocytogenes. J Immunol 2008, 180:5991-5999.
5. Janeway C.A., Medzhitov R. Introduction: the role of innate immunity in the adaptive immune response. Semin Immunol 1998, 10:349-350.
6. Medzhitov R. Approaching the asymptote: 20 years later. Immunity 2009, 30:766-775.
7. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 5:987-995.
8. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
9. Pasare C., Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003, 299:1033-1036.
10. Pasare C., Medzhitov R. Toll-dependent control mechanisms of CD4 T cell activation. Immunity 2004, 21:733-741.
11. Pasare C., Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature 2005, 438:364-368.
12. Gelman A.E., LaRosa D.F., Zhang J., et al. The adaptor molecule MyD88 activates PI-3 kinase signaling in CD4+ T cells and enables CpG oligodeoxynucleotide-mediated costimulation. Immunity 2006, 25:783-793.
13. Gelman A.E., Zhang J., Choi Y., Turka L.A. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol 2004, 172:6065-6073.
14. Dai J., Liu B., Li Z. Regulatory T cells and Toll-like receptors: what is the missing link?. Int Immunopharmacol 2009, 9:528-533.
15. Kulkarni R., Behboudi S., Sharif S. Insights into the role of Toll-like receptors in modulation of T cell responses. Cell Tissue Res 2010, 1-12.
16. Chen Q., Davidson T.S., Huter E.N., Shevach E.M. Engagement of TLR2 does not reverse the suppressor function of mouse regulatory T cells, but promotes their survival. J Immunol 2009, 183:4458-4466.
17. Sutmuller R.P., den Brok M.H., Kramer M., et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest 2006, 116:485-494.
18. Sutmuller R.P., Morgan M.E., Netea M.G., Grauer O., Adema G.J. Toll-like receptors on regulatory T cells: expanding immune regulation. Trends Immunol 2006, 27:387-393.
19. Liu H., Komai-Koma M., Xu D., Liew F.Y. Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells. Proc Natl Acad Sci U S A 2006, 103:7048-7053.
20. Oberg H.H., Ly T.T., Ussat S., Meyer T., Kabelitz D., Wesch D. Differential but direct abolishment of human regulatory T cell suppressive capacity by various TLR2 ligands. J Immunol 2010, 184:4733-4740.
21. Peng G., Guo Z., Kiniwa Y., et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 2005, 309:1380-1384.
22. Chiffoleau E., Heslan J.M., Heslan M., Louvet C., Condamine T., Cuturi M.C. TLR9 ligand enhances proliferation of rat CD4+ T cell and modulates suppressive activity mediated by CD4+ CD25+ T cell. Int Immunol 2007, 19:193-201.
23. Caron G., Duluc D., Fremaux I., et al. Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells. J Immunol 2005, 175:1551-1557.
24. Fukata M., Breglio K., Chen A., et al. The myeloid differentiation factor 88 (MyD88) is required for CD4+ T cell effector function in a murine model of inflammatory bowel disease. J Immunol 2008, 180:1886-1894.
25. Goldstein D.R., Tesar B.M., Akira S., Lakkis F.G. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest 2003, 111:1571-1578.
26. McKay D., Shigeoka A., Rubinstein M., Surh C., Sprent J. Simultaneous deletion of MyD88 and Trif delays major histocompatibility and minor antigen mismatch allograft rejection. Eur J Immunol 2006, 36:1994-2002.
27. Chen L., Wang T., Zhou P., et al. TLR engagement prevents transplantation tolerance. Am J Transplant 2006, 6:2282-2291.
28. Thornley T.B., Brehm M.A., Markees T.G., et al. TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts. J Immunol 2006, 176:1561-1570.
29. Yang Y., Huang C.T., Huang X., Pardoll D.M. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 2004, 5:508-515.
30. Stetson D.B., Medzhitov R. Type I interferons in host defense. Immunity 2006, 25:373-381.
31. Arbour N.C., Lorenz E., Schutte B.C., et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000, 25:187-191.
32. Palmer S.M., Klimecki W., Yu L., et al. Genetic regulation of rejection and survival following human lung transplantation by the innate immune receptor CD14. Am J Transplant 2007, 7:693-699.
33. Palmer S.M., Burch L.H., Mir S., et al. Donor polymorphisms in Toll-like receptor-4 influence the development of rejection after renal transplantation. Clin Transplant 2006, 20:30-36.
34. Ducloux D., Deschamps M., Yannaraki M., et al. Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. Kidney Int 2005, 67:2454-2461.
35. Bochud P.Y., Chien J.W., Marr K.A., et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008, 359:1766-1777.
36. Eid A.J., Brown R.A., Paya C.V., Razonable R.R. Association between toll-like receptor polymorphisms and the outcome of liver transplantation for chronic hepatitis C virus. Transplantation 2007, 84:511-516.
37. Kumagai Y., Akira S. Identification and functions of pattern-recognition receptors. J Allergy Clin Immunol 2010, 125:985-992.
38. Penack O., Smith O.M., Cunningham-Bussel A., et al. NOD2 regulates hematopoietic cell function during graft-versus-host disease. J Exp Med 2009, 206:2101-2110.
39. Holler E., Rogler G., Brenmoehl J., et al. The role of genetic variants of NOD2/CARD15, a receptor of the innate immune system, in GvHD and complications following related and unrelated donor haematopoietic stem cell transplantation. Int J Immunogenet 2008, 35:381-384.
40. Holler E., Rogler G., Brenmoehl J., et al. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood 2006, 107:4189-4193.
41. Granell M., Urbano-Ispizua A., Arostegui J.I., et al. Effect of NOD2/CARD15 variants in T-cell depleted allogeneic stem cell transplantation. Haematologica 2006, 91:1372-1376.
42. Sairafi D., Uzunel M., Remberger M., Ringden O., Mattsson J. No impact of NOD2/CARD15 on outcome after SCT. Bone Marrow Transplant 2008, 41:961-964.
43. Rao D.A., Pober J.S. Endothelial injury, alarmins, and allograft rejection. Crit Rev Immunol 2008, 28:229-248.
44. Srikrishna G., Freeze H.H. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia 2009, 11:615-628.
45. Foell D., Wittkowski H., Vogl T., Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007, 81:28-37.
46. Sato S., St-Pierre C., Bhaumik P., Nieminen J. Galectins in innate immunity: dual functions of host soluble beta-galactoside-binding lectins as damage-associated molecular patterns (DAMPs) and as receptors for pathogen-associated molecular patterns (PAMPs). Immunol Rev 2009, 230:172-187.
47. Bianchi M.E. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007, 81:1-5.
48. Huang Y., Yin H., Han J., et al. Extracellular HMGB1 functions as an innate immune-mediator implicated in murine cardiac allograft acute rejection. Am J Transplant 2007, 7:799-808.
49. Duan L., Wang C.Y., Chen J., et al. High-mobility group box 1 promotes early acute allograft rejection by enhancing IL-6-dependent Th17 alloreactive response. Lab Invest 2010.
50. Stockinger S., Decker T. Novel functions of type I interferons revealed by infection studies with Listeria monocytogenes. Immunobiology 2008, 213:889-897.
51. Welsh R.M., Markees T.G., Woda B.A., et al. Virus-induced abrogation of transplantation tolerance induced by donor-specific transfusion and anti-CD154 antibody. J Virol 2000, 74:2210-2218.
52. Cook C.H., Bickerstaff A.A., Wang J.J., et al. Disruption of murine cardiac allograft acceptance by latent cytomegalovirus. Am J Transplant 2009, 9:42-53.
53. Perona-Wright G., Mohrs K., Mohrs M. Sustained signaling by canonical helper T cell cytokines throughout the reactive lymph node. Nat Immunol 2010, 11:520-526.
54. Bushell A., Morris P.J., Wood K.J. Transplantation tolerance induced by antigen pretreatment and depleting anti-CD4 antibody depends on CD4+ T cell regulation during the induction phase of the response. Eur J Immunol 1995, 25:2643-2649.
55. Cobbold S.P., Adams E., Marshall S.E., Davies J.D., Waldmann H. Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8. Immunol Rev 1996, 149:5-33.
56. Elster E.A., Xu H., Tadaki D.K., et al. Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates. Transplantation 2001, 72:1473-1478.
57. Braud C., Baeten D., Giral M., et al. Immunosuppressive drug-free operational immune tolerance in human kidney transplant recipients: part I. Blood gene expression statistical analysis. J Cell Biochem 2008, 103:1681-1692.
58. Ashton-Chess J., Giral M., Brouard S., Soulillou J.P. Spontaneous operational tolerance after immunosuppressive drug withdrawal in clinical renal allotransplantation. Transplantation 2007, 84:1215-1219.
59. Golshayan D., Wyss J.C., Buckland M., Hernandez-Fuentes M., Lechler R.I. Differential role of naive and memory CD4 T-cell subsets in primary alloresponses. Am J Transplant 2010, 10:1749-1759.
60. Wu Z., Bensinger S.J., Zhang J., et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004, 10:87-92.
61. Valujskikh A., Pantenburg B., Heeger P.S. Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice. Am J Transplant 2002, 2:501-509.
62. Tanaka K., Albin M.J., Yuan X., et al. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol 2007, 179:5204-5210.
63. Zhang Y., Chung Y., Bishop C., et al. Regulation of T cell activation and tolerance by PDL2. Proc Natl Acad Sci U S A 2006, 103:11695-11700.
64. Wang T., Ahmed E.B., Chen L., et al. Infection with the intracellular bacterium, Listeria monocytogenes, overrides established tolerance in a mouse cardiac allograft model. Am J Transplant 2010, 10:1524-1533.
65. de Vries V.C., Wasiuk A., Bennett K.A., et al. Mast cell degranulation breaks peripheral tolerance. Am J Transplant 2009, 9:2270-2280.
66. Fishman J.A., Rubin R.H. Infection in organ-transplant recipients. N Engl J Med 1998, 338:1741-1751.
67. Patel R., Paya C.V. Infections in solid-organ transplant recipients. Clin Microbiol Rev 1997, 10:86-124.
68. Rubin R.H. Temporal aspects of transplant infectious disease. Transpl Infect Dis 2003, 5:63-64.
69. Singh N. Infections in solid organ transplant recipients. Curr Opin Infect Dis 2000, 13:343-347.
70. Palmer S.M., Burch L.H., Trindade A.J., et al. Innate immunity influences long-term outcomes after human lung transplant. Am J Respir Crit Care Med 2005, 171:780-785.
71. Sigurdsson L., Reyes J., Kocoshis S.A., Mazariegos G., Abu-Elmagd K., Green M. Bacteremia after intestinal transplantation in children correlates temporally with rejection or gastrointestinal lymphoproliferative disease. Transplantation 2000, 70:302-305.
72. Bando K., Paradis I.L., Similo S., et al. Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. J Thorac Cardiovasc Surg 1995, 110:4-13. discussion 13-14.
73. Girgis R.E., Tu I., Berry G.J., et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant 1996, 15:1200-1208.
74. Heng D., Sharples L.D., McNeil K., Stewart S., Wreghitt T., Wallwork J. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant 1998, 17:1255-1263.
75. Glanville A.R., Gencay M., Tamm M., et al. Chlamydia pneumoniae infection after lung transplantation. J Heart Lung Transplant 2005, 24:131-136.
76. Husain S., Kahane S., Friedman M.G., et al. Simkania negevensis in bronchoalveolar lavage of lung transplant recipients: a possible association with acute rejection. Transplantation 2007, 83:138-143.
77. Wiebe K., Fraund S., Steinmuller C., Steinhoff G. Rat cytomegalovirus and Listeria monocytogenes infection enhance chronic rejection after allogenic rat lung transplantation. Transpl Int 2005, 18:1166-1174.
78. Cicalese L., Sileri P., Green M., Abu-Elmagd K., Kocoshis S., Reyes J. Bacterial translocation in clinical intestinal transplantation. Transplantation 2001, 71:1414-1417.
79. Garbino J., Romand J.A., Pittet D., Giostra E., Mentha G., Suter P. Infection and rejection in liver transplant patients: a 10-year Swiss single-centre experience. Swiss Med Wkly 2005, 135:587-593.
80. Winters G.L., Costanzo-Nordin M.R., O'Sullivan E.J., et al. Predictors of late acute orthotopic heart transplant rejection. Circulation 1989, 80:106-110.